Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337612

Cover Image

PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337612

Single-Use Bioreactors Market Size and Share Analysis by Product Type, Type, Cell Type, Molecule Type, Application, Usage Type, End User - Global Industry Demand Forecast to 2030

PUBLISHED:
PAGES: 210 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
Printable PDF (Group User License)
USD 6400
Printable PDF (Enterprise License)
USD 8400

Add to Cart

The single-use bioreactors market will grow at a 18.8% CAGR in the years to come, and will reach to a value of USD 13,595.9 million by 2030. The growth of the industry is powered by the increasing prevalence of infectious and chronic diseases.

There has been a significant increase in the number of infectious diseases worldwide. The COVID-19 pandemic has led to the rapid adoption of advanced technologies by life sciences and biopharmaceutical firms to produce vaccines quickly and on a large scale.

This has brought about a growing demand for single-use systems, which are flexible and modular, allowing for local manufacturing facilities in emerging nations that lack investments. These systems are mainly utilized in the production of viral vaccines.

To better understand the COVID-19 virus's behavior in humans, some manufacturers are using bioreactors to cultivate suitable host cells. Additionally, several companies have entered in collaborations to enhance their market positions.

Startups and small to medium-sized enterprises are increasingly using bioreactors due to the high costs involved in setting up traditional biomanufacturing facilities. These companies produce fewer batches annually and find stainless steel facilities expensive.

As a result, they are adopting single-use systems that require less capital investment and eliminate the need for validation, sterilization, cleaning, and changeover processes.

The system category dominates the market, with 55% of the revenue share in 2022. This is due to its widespread use in biopharmaceutical manufacturing facilities that require high product yields. These systems are cost-effective, versatile, and capable of large-scale production, meeting the increasing demand for biotherapeutics like antibodies, hormones, vaccines, and enzymes.

North America dominates the single-use bioreactors market due to factors like the high prevalence of chronic diseases, presence of top players, advanced healthcare facilities, technological advancements and strong research and development initiatives.

Within North America, the U.S. plays a significant role, driven by the adoption of innovative technologies, public awareness regarding disease prevention, government support, and advanced healthcare infrastructure.

The vaccines category had the largest revenue share in 2022 due to the increase in infectious diseases. The demand for mass production of vaccines for prevention and treatment purposes has increased. The COVID-19 pandemic further accelerated vaccine manufacturing, leading to the adoption of single-use bioreactors.

Lab-scale production is leading the industry. This is due to the fact that the biopharma industry requires the frequent use of bioreactors for various preclinical and clinical research purposes.

Moreover, the increasing acceptance and progressions in single-use technologies will all boost the expansion of the industry, a great deal in the future.

It is because of the increasing research and development activities in the medical industry, that the demand for single-use bioreactors will continue to rise in the years to come.

Product Code: 12634

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product type
    • 1.4.2. Market size breakdown, by type
    • 1.4.3. Market size breakdown, by cell type
    • 1.4.4. Market size breakdown, by molecule type
    • 1.4.5. Market size breakdown, by application
    • 1.4.6. Market size breakdown, by usage type
    • 1.4.7. Market size breakdown, by end user
    • 1.4.8. Market size breakdown, by region
    • 1.4.9. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

  • 6.1. Market Dynamics
    • 6.1.1. Trends
    • 6.1.2. Drivers
    • 6.1.3. Restraints/challenges
    • 6.1.4. Impact analysis of drivers/restraints
  • 6.2. Impact of COVID-19
  • 6.3. Porter's Five Forces Analysis
    • 6.3.1. Bargaining power of buyers
    • 6.3.2. Bargaining power of suppliers
    • 6.3.3. Threat of new entrants
    • 6.3.4. Intensity of rivalry
    • 6.3.5. Threat of substitutes

Chapter 7. Global Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product type (2017-2030)
  • 7.3. Market Revenue, by Type (2017-2030)
  • 7.4. Market Revenue, by Cell type (2017-2030)
  • 7.5. Market Revenue, by Molecule type (2017-2030)
  • 7.6. Market Revenue, by Application (2017-2030)
  • 7.7. Market Revenue, by Usage type (2017-2030)
  • 7.8. Market Revenue, by End user (2017-2030)
  • 7.9. Market Revenue, by Region (2017-2030)

Chapter 8. North America Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product type (2017-2030)
  • 8.3. Market Revenue, by Type (2017-2030)
  • 8.4. Market Revenue, by Cell type (2017-2030)
  • 8.5. Market Revenue, by Molecule type (2017-2030)
  • 8.6. Market Revenue, by Application (2017-2030)
  • 8.7. Market Revenue, by Usage type (2017-2030)
  • 8.8. Market Revenue, by End user (2017-2030)
  • 8.9. Market Revenue, by Country (2017-2030)

Chapter 9. Europe Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product type (2017-2030)
  • 9.3. Market Revenue, by Type (2017-2030)
  • 9.4. Market Revenue, by Cell type (2017-2030)
  • 9.5. Market Revenue, by Molecule type (2017-2030)
  • 9.6. Market Revenue, by Application (2017-2030)
  • 9.7. Market Revenue, by Usage type (2017-2030)
  • 9.8. Market Revenue, by End user (2017-2030)
  • 9.9. Market Revenue, by Country (2017-2030)

Chapter 10. APAC Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product type (2017-2030)
  • 10.3. Market Revenue, by Type (2017-2030)
  • 10.4. Market Revenue, by Cell type (2017-2030)
  • 10.5. Market Revenue, by Molecule type (2017-2030)
  • 10.6. Market Revenue, by Application (2017-2030)
  • 10.7. Market Revenue, by Usage type (2017-2030)
  • 10.8. Market Revenue, by End user (2017-2030)
  • 10.9. Market Revenue, by Country (2017-2030)

Chapter 11. LATAM Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product type (2017-2030)
  • 11.3. Market Revenue, by Type (2017-2030)
  • 11.4. Market Revenue, by Cell type (2017-2030)
  • 11.5. Market Revenue, by Molecule type (2017-2030)
  • 11.6. Market Revenue, by Application (2017-2030)
  • 11.7. Market Revenue, by Usage type (2017-2030)
  • 11.8. Market Revenue, by End user (2017-2030)
  • 11.9. Market Revenue, by Country (2017-2030)

Chapter 12. MEA Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product type (2017-2030)
  • 12.3. Market Revenue, by Type (2017-2030)
  • 12.4. Market Revenue, by Cell type (2017-2030)
  • 12.5. Market Revenue, by Molecule type (2017-2030)
  • 12.6. Market Revenue, by Application (2017-2030)
  • 12.7. Market Revenue, by Usage type (2017-2030)
  • 12.8. Market Revenue, by End user (2017-2030)
  • 12.9. Market Revenue, by Country (2017-2030)

Chapter 13. U.S. Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product type (2017-2030)
  • 13.3. Market Revenue, by Type (2017-2030)
  • 13.4. Market Revenue, by Cell type (2017-2030)
  • 13.5. Market Revenue, by Molecule type (2017-2030)
  • 13.6. Market Revenue, by Application (2017-2030)
  • 13.7. Market Revenue, by Usage type (2017-2030)
  • 13.8. Market Revenue, by End user (2017-2030)

Chapter 14. Canada Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product type (2017-2030)
  • 14.3. Market Revenue, by Type (2017-2030)
  • 14.4. Market Revenue, by Cell type (2017-2030)
  • 14.5. Market Revenue, by Molecule type (2017-2030)
  • 14.6. Market Revenue, by Application (2017-2030)
  • 14.7. Market Revenue, by Usage type (2017-2030)
  • 14.8. Market Revenue, by End user (2017-2030)

Chapter 15. Germany Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product type (2017-2030)
  • 15.3. Market Revenue, by Type (2017-2030)
  • 15.4. Market Revenue, by Cell type (2017-2030)
  • 15.5. Market Revenue, by Molecule type (2017-2030)
  • 15.6. Market Revenue, by Application (2017-2030)
  • 15.7. Market Revenue, by Usage type (2017-2030)
  • 15.8. Market Revenue, by End user (2017-2030)

Chapter 16. France Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product type (2017-2030)
  • 16.3. Market Revenue, by Type (2017-2030)
  • 16.4. Market Revenue, by Cell type (2017-2030)
  • 16.5. Market Revenue, by Molecule type (2017-2030)
  • 16.6. Market Revenue, by Application (2017-2030)
  • 16.7. Market Revenue, by Usage type (2017-2030)
  • 16.8. Market Revenue, by End user (2017-2030)

Chapter 17. U.K. Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product type (2017-2030)
  • 17.3. Market Revenue, by Type (2017-2030)
  • 17.4. Market Revenue, by Cell type (2017-2030)
  • 17.5. Market Revenue, by Molecule type (2017-2030)
  • 17.6. Market Revenue, by Application (2017-2030)
  • 17.7. Market Revenue, by Usage type (2017-2030)
  • 17.8. Market Revenue, by End user (2017-2030)

Chapter 18. Italy Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product type (2017-2030)
  • 18.3. Market Revenue, by Type (2017-2030)
  • 18.4. Market Revenue, by Cell type (2017-2030)
  • 18.5. Market Revenue, by Molecule type (2017-2030)
  • 18.6. Market Revenue, by Application (2017-2030)
  • 18.7. Market Revenue, by Usage type (2017-2030)
  • 18.8. Market Revenue, by End user (2017-2030)

Chapter 19. Spain Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product type (2017-2030)
  • 19.3. Market Revenue, by Type (2017-2030)
  • 19.4. Market Revenue, by Cell type (2017-2030)
  • 19.5. Market Revenue, by Molecule type (2017-2030)
  • 19.6. Market Revenue, by Application (2017-2030)
  • 19.7. Market Revenue, by Usage type (2017-2030)
  • 19.8. Market Revenue, by End user (2017-2030)

Chapter 20. Japan Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product type (2017-2030)
  • 20.3. Market Revenue, by Type (2017-2030)
  • 20.4. Market Revenue, by Cell type (2017-2030)
  • 20.5. Market Revenue, by Molecule type (2017-2030)
  • 20.6. Market Revenue, by Application (2017-2030)
  • 20.7. Market Revenue, by Usage type (2017-2030)
  • 20.8. Market Revenue, by End user (2017-2030)

Chapter 21. China Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product type (2017-2030)
  • 21.3. Market Revenue, by Type (2017-2030)
  • 21.4. Market Revenue, by Cell type (2017-2030)
  • 21.5. Market Revenue, by Molecule type (2017-2030)
  • 21.6. Market Revenue, by Application (2017-2030)
  • 21.7. Market Revenue, by Usage type (2017-2030)
  • 21.8. Market Revenue, by End user (2017-2030)

Chapter 22. India Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product type (2017-2030)
  • 22.3. Market Revenue, by Type (2017-2030)
  • 22.4. Market Revenue, by Cell type (2017-2030)
  • 22.5. Market Revenue, by Molecule type (2017-2030)
  • 22.6. Market Revenue, by Application (2017-2030)
  • 22.7. Market Revenue, by Usage type (2017-2030)
  • 22.8. Market Revenue, by End user (2017-2030)

Chapter 23. Australia Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product type (2017-2030)
  • 23.3. Market Revenue, by Type (2017-2030)
  • 23.4. Market Revenue, by Cell type (2017-2030)
  • 23.5. Market Revenue, by Molecule type (2017-2030)
  • 23.6. Market Revenue, by Application (2017-2030)
  • 23.7. Market Revenue, by Usage type (2017-2030)
  • 23.8. Market Revenue, by End user (2017-2030)

Chapter 24. South Korea Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product type (2017-2030)
  • 24.3. Market Revenue, by Type (2017-2030)
  • 24.4. Market Revenue, by Cell type (2017-2030)
  • 24.5. Market Revenue, by Molecule type (2017-2030)
  • 24.6. Market Revenue, by Application (2017-2030)
  • 24.7. Market Revenue, by Usage type (2017-2030)
  • 24.8. Market Revenue, by End user (2017-2030)

Chapter 25. Brazil Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product type (2017-2030)
  • 25.3. Market Revenue, by Type (2017-2030)
  • 25.4. Market Revenue, by Cell type (2017-2030)
  • 25.5. Market Revenue, by Molecule type (2017-2030)
  • 25.6. Market Revenue, by Application (2017-2030)
  • 25.7. Market Revenue, by Usage type (2017-2030)
  • 25.8. Market Revenue, by End user (2017-2030)

Chapter 26. Mexico Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product type (2017-2030)
  • 26.3. Market Revenue, by Type (2017-2030)
  • 26.4. Market Revenue, by Cell type (2017-2030)
  • 26.5. Market Revenue, by Molecule type (2017-2030)
  • 26.6. Market Revenue, by Application (2017-2030)
  • 26.7. Market Revenue, by Usage type (2017-2030)
  • 26.8. Market Revenue, by End user (2017-2030)

Chapter 27. Saudi Arabia Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product type (2017-2030)
  • 27.3. Market Revenue, by Type (2017-2030)
  • 27.4. Market Revenue, by Cell type (2017-2030)
  • 27.5. Market Revenue, by Molecule type (2017-2030)
  • 27.6. Market Revenue, by Application (2017-2030)
  • 27.7. Market Revenue, by Usage type (2017-2030)
  • 27.8. Market Revenue, by End user (2017-2030)

Chapter 28. South Africa Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product type (2017-2030)
  • 28.3. Market Revenue, by Type (2017-2030)
  • 28.4. Market Revenue, by Cell type (2017-2030)
  • 28.5. Market Revenue, by Molecule type (2017-2030)
  • 28.6. Market Revenue, by Application (2017-2030)
  • 28.7. Market Revenue, by Usage type (2017-2030)
  • 28.8. Market Revenue, by End user (2017-2030)

Chapter 29. U.A.E. Market

  • 29.1. Overview
  • 29.2. Market Revenue, by Product type (2017-2030)
  • 29.3. Market Revenue, by Type (2017-2030)
  • 29.4. Market Revenue, by Cell type (2017-2030)
  • 29.5. Market Revenue, by Molecule type (2017-2030)
  • 29.6. Market Revenue, by Application (2017-2030)
  • 29.7. Market Revenue, by Usage type (2017-2030)
  • 29.8. Market Revenue, by End user (2017-2030)

Chapter 30. Competitive Landscape

  • 30.1. List of Market Players and their Offerings
  • 30.2. Competitive Benchmarking of Key Players
  • 30.3. Product Benchmarking of Key Players
  • 30.4. Recent Strategic Developments

Chapter 31. Company Profiles

  • 31.1. Sartorius AG
    • 31.1.1. Business overview
    • 31.1.2. Product and service offerings
    • 31.1.3. Key financial summary
  • 31.2. Thermo Fisher Scientific Inc
    • 31.2.1. Business overview
    • 31.2.2. Product and service offerings
    • 31.2.3. Key financial summary
  • 31.3. Getinge AB
    • 31.3.1. Business overview
    • 31.3.2. Product and service offerings
    • 31.3.3. Key financial summary
  • 31.4. Merck KGaA
    • 31.4.1. Business overview
    • 31.4.2. Product and service offerings
    • 31.4.3. Key financial summary
  • 31.5. Eppendorf SE
    • 31.5.1. Business overview
    • 31.5.2. Product and service offerings
    • 31.5.3. Key financial summary
  • 31.6. PBS Biotech, Inc
    • 31.6.1. Business overview
    • 31.6.2. Product and service offerings
  • 31.7. Distek, Inc
    • 31.7.1. Business overview
    • 31.7.2. Product and service offerings
  • 31.8. ABEC Inc.
    • 31.8.1. Business overview
    • 31.8.2. Product and service offerings
  • 31.9. G&G Technologies Inc
    • 31.9.1. Business overview
    • 31.9.2. Product and service offerings
  • 31.10. Solida Biotech GmBH
    • 31.10.1. Business overview
    • 31.10.2. Product and service offerings
  • 31.11. Surplus Solutions LLC
    • 31.11.1. Business overview
    • 31.11.2. Product and service offerings
  • 31.12. Esco Micro Pte Ltd
    • 31.12.1. Business overview
    • 31.12.2. Product and service offerings
  • 31.13. Celltainer Biotech BV
    • 31.13.1. Business overview
    • 31.13.2. Product and service offerings
  • 31.14. Stobbe Pharma GmbH
    • 31.14.1. Business overview
    • 31.14.2. Product and service offerings
  • 31.15. SATAKE MultiMix Corporation
    • 31.15.1. Business overview
    • 31.15.2. Product and service offerings

Chapter 32. Appendix

  • 32.1. Abbreviations
  • 32.2. Sources and References
  • 32.3. Related Reports
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!